FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

Check this box if no longer subject to
Section 16. Form 4 or Form 5
obligations may continue. See
Instruction 1(b).

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

**OMB APPROVAL** OMB Number: Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* Schenkein David P							2. Issuer Name and Ticker or Trading Symbol AGIOS PHARMACEUTICALS INC								5. Relationship of Reporting Person(s) to Issuer (Check all applicable)  X Director 10% Owner				
(Last) (First) (Middle) C/O AGIOS PHARMACEUTICALS, INC. 88 SIDNEY STREET						3. Date of Earliest Transaction (Month/Day/Year) 10/04/2017								X Officer (give title Other (specify below)  Chief Executive Officer					
(Street) CAMBRIDGE MA 02139 (City) (State) (Zip)					_   4. I _	4. If Amendment, Date of Original Filed (Month/Day/Year)  6. Individual or Joint/Group Filing (Check Applica Line)  X Form filed by One Reporting Person  Form filed by More than One Reporting Person												on	
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																			
1. Title of Security (Instr. 3)  2. Transaction Date (Month/Day/						Exe	cutio ny	Deemed cution Date, ny nth/Day/Year)		ction Instr.	4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and			5. Amount of Securities Beneficially Owned Following Reported		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership	
									Code	v	Amount	(A) or (D)	Price	Tran		etion(s) and 4)			Instr. 4)
Common stock 10/04/20						)17			M <sup>(1)</sup>		80,000	A	\$0.302	25	5 80,000		D		
Common stock 10/04/20						017			S <sup>(2)</sup>		80,000	D	\$70.14	(3)	) 0		D		
Common stock															271,772		I I I		See Footnote <sup>(4)</sup>
Common stock															79,082		I		See cootnote <sup>(5)</sup>
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																			
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security		3A. Deer Execution if any (Month/E		4. Transaction Code (Instr. 8)				6. Date Exerc Expiration Da (Month/Day/Y		ate	7. Title and Amou of Securities Underlying Derivative Securi (Instr. 3 and 4)		Derivative Security		9. Numbo derivativ Securitie Beneficia Owned Followin Reported Transact (Instr. 4)	e es ally g	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4	Beneficial Ownership (Instr. 4)
					Code	v	(A)	(D)	Date Exercis	able	Expiration Date	Title	Amoun or Number of Shares						
Stock option (right to buy)	\$0.3025	10/04/2017			M <sup>(1)</sup>		80,000		(6)		08/12/2019	Common stock	80,000	) !	\$0.00	32,656		D	

## **Explanation of Responses:**

- 1. This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
- 2. This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
- 3. The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of \$70.00 to \$70.68. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
- 4. Shares held by David P. Schenkein 2004 Revocable Trust, of which the reporting person is trustee and beneficiary.
- 5. Shares held by Amy P. Schenkein 2004 Revocable Trust, of which the reporting person's spouse is trustee and beneficiary.
- 6. This option was granted on August 13, 2009. The shares underlying this option vest as to 25% of the shares on August 1, 2010, with the remaining 75% vesting in 36 equal monthly installments thereafter.

## Remarks:

/s/ Andrew Hirsch, as Attorney in Fact for David Schenkein

10/05/2017

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.